Literature DB >> 11407899

Human mesenchymal stem cells maintain transgene expression during expansion and differentiation.

K Lee1, M K Majumdar, D Buyaner, J K Hendricks, M F Pittenger, J D Mosca.   

Abstract

Human adult bone marrow contains both hematopoietic stem cells that generate cells of all hematopoietic lineages and human mesenchymal stem cells (hMSCs), which support hematopoiesis and contribute to the regeneration of multiple connective tissues. The goal of the current study was to demonstrate that transduced hMSCs maintain transgene expression after stem cell differentiation in vitro and in vivo. We have introduced genes into cultured hMSCs by retroviral vector transfer and demonstrated long-term in vitro and in vivo expression of human interleukin 3 (hIL-3) and green fluorescent protein (GFP). Protocols were developed to achieve transduction efficiencies of 80-90% in these stem cells. In vitro expression of hIL-3 averaged 350 ng/10(6)cells/24 h over 17 passages (> 6 months) and GFP expression was stable over the same time period. Transduced hMSCs were able to differentiate into osteogenic, adipogenic, and chondrogenic lineages and maintained transgene expression after differentiation. Parallel studies were performed in vivo using NOD/SCID mice. Human MSCs expressing hIL-3 were cultured on several matrices and then delivered by subcutaneous, intravenous, and intraperitoneal routes. Sampling of peripheral blood demonstrated that systemic hIL-3 expression was maintained in the range of 100-800 pg/ml over a period of 3 months. These results illustrate the ability of hMSCs to express genes of therapeutic potential and demonstrate their potential clinical utility as cellular vehicles for systemic gene delivery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11407899     DOI: 10.1006/mthe.2001.0327

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  36 in total

Review 1.  Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases.

Authors:  Jakob Reiser; Xian-Yang Zhang; Charles S Hemenway; Debasis Mondal; Leena Pradhan; Vincent F La Russa
Journal:  Expert Opin Biol Ther       Date:  2005-12       Impact factor: 4.388

Review 2.  Mesenchymal stem cells as delivery vectors for anti-tumor therapy.

Authors:  Zhenzhen Li; Dongmei Fan; Dongsheng Xiong
Journal:  Stem Cell Investig       Date:  2015-03-26

3.  Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells.

Authors:  J L Dembinski; E L Spaeth; J Fueyo; C Gomez-Manzano; M Studeny; M Andreeff; F C Marini
Journal:  Cancer Gene Ther       Date:  2009-10-30       Impact factor: 5.987

Review 4.  Molecular advances in reporter genes: the need to witness the function of stem cells in failing heart in vivo.

Authors:  Silvia Agostini; Fabio A Recchia; Vincenzo Lionetti
Journal:  Stem Cell Rev Rep       Date:  2012-06       Impact factor: 5.739

Review 5.  Genetically modified mesenchymal stem cells for improved islet transplantation.

Authors:  Hao Wu; Zhaoyang Ye; Ram I Mahato
Journal:  Mol Pharm       Date:  2011-07-07       Impact factor: 4.939

Review 6.  Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?

Authors:  Catherine Tang; Pamela J Russell; Rosetta Martiniello-Wilks; John E J Rasko; Aparajita Khatri
Journal:  Stem Cells       Date:  2010-09       Impact factor: 6.277

7.  Comparison of drug and cell-based delivery: engineered adult mesenchymal stem cells expressing soluble tumor necrosis factor receptor II prevent arthritis in mouse and rat animal models.

Authors:  Linda N Liu; Gang Wang; Kyle Hendricks; Keunmyoung Lee; Ernst Bohnlein; Uwe Junker; Joseph D Mosca
Journal:  Stem Cells Transl Med       Date:  2013-04-16       Impact factor: 6.940

8.  Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins.

Authors:  Xian-Yang Zhang; Vincent F La Russa; Jakob Reiser
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Management of Liver Failure: From Transplantation to Cell-Based Therapy.

Authors:  Maria Giovanna Francipane; Melchiorre Cervello; Giovanni Battista Vizzini; Giada Pietrosi; Giuseppe Montalto
Journal:  Cell Med       Date:  2011-06-01

10.  Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.

Authors:  Laura S Sasportas; Randa Kasmieh; Hiroaki Wakimoto; Shawn Hingtgen; Jeroen A J M van de Water; Gayatry Mohapatra; Jose Luiz Figueiredo; Robert L Martuza; Ralph Weissleder; Khalid Shah
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.